Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR201 vs Cosentyx in Healthy Male Subjects
NCT06126718Phase 1Completed
- Sponsor
- BioRay Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of secukinumab in psoriasis (2 arms), sponsored by BioRay Pharmaceutical. Primary endpoints: Area Under the Curve from Time 0 to Infinity at Day 112 and Maximum Plasma Concentration at Day 112. Started Feb 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06126718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126718.